Most federally funded, multisite studies already require oversight by a single institutional review board (sIRB), and soon that likely will be true for U.S. Food and Drug Administration-regulated studies. It’s no secret that sIRB review presents challenges for study teams, especially those managing investigator-initiated studies. This session will help you understand your responsibilities related to sIRB review and point you to resources you can take advantage of.

CEU: 1.00 ACRP

Speakers:

• Polly Goodman, Associate Director of Regulatory Affairs Operations, SMART IRB, Harvard Catalyst | The Harvard Clinical and Translational Science Center

• Michael Linke, PhD, Adjunct Professor/Director of Education, University of Cincinnati/SMART IRB

Watch a Sneak Peek into the Session Content: